Determination of lipoprotein(a) concentrations and apolipoprotein(a) molecular weights in diabetic patients

Diabetes Metab. 2000 Apr;26(2):107-12.

Abstract

Lipoprotein(a) (Lp(a)) with atherogenic and thrombotic properties has been frequently studied in diabetes, because a high cardiovascular risk has been reported both in type 1 and type 2 diabetes. Few studies have considered genetic factors, especially the isoforms of apolipoprotein(a). The aim of this work is to determine the distribution of apo(a) phenotypes in the serum of 148 diabetic patients (59 type 1, 89 type 2) with or without vascular complications. Apo(a) phenotypes are determined using 4-15% sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by immunoblotting (PhastSystem - Pharmacia). An inverse relationship is observed between Lp(a) serum concentration and the apparent molecular mass of apo(a) isoforms: type 1 r=- 0.61, p<0.01; type 2 r=- 0.55, p<0.01. The frequency of apo(a) isoforms is significantly different between type 1 and type 2 diabetes mellitus. A higher prevalence of isoforms of low molecular weight was observed in the type 2 diabetic population.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Apolipoproteins / blood
  • Apolipoproteins / chemistry*
  • Apolipoproteins / genetics
  • Apoprotein(a)
  • Diabetes Mellitus, Type 1 / blood*
  • Diabetes Mellitus, Type 2 / blood*
  • Electrophoresis, Polyacrylamide Gel
  • Female
  • Heterozygote
  • Homozygote
  • Humans
  • Immunoblotting
  • Lipoprotein(a) / blood*
  • Lipoprotein(a) / chemistry*
  • Lipoprotein(a) / genetics
  • Male
  • Middle Aged
  • Molecular Weight
  • Phenotype
  • Protein Isoforms / blood
  • Protein Isoforms / chemistry
  • Protein Isoforms / genetics
  • Reference Values

Substances

  • Apolipoproteins
  • Lipoprotein(a)
  • Protein Isoforms
  • Apoprotein(a)